Johnson & Johnson Stock Price, News & Analysis (NYSE:JNJ)

$148.14 0.78 (0.53 %)
(As of 01/23/2018 10:52 AM ET)
Previous Close$147.36
Today's Range$146.72 - $148.14
52-Week Range$110.76 - $148.32
Volume7.01 million shs
Average Volume6.78 million shs
Market Capitalization$389.20 billion
P/E Ratio25.72
Dividend Yield2.29%
Beta0.8

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:JNJ
CUSIP47816010
Phone+1-732-5242455

Debt

Debt-to-Equity Ratio0.36%
Current Ratio1.32%
Quick Ratio1.02%

Price-To-Earnings

Trailing P/E Ratio25.71875
Forward P/E Ratio20.35
P/E Growth2.76

Sales & Book Value

Annual Sales$71.89 billion
Price / Sales5.54
Cash Flow$8.32 per share
Price / Cash17.80
Book Value$25.88 per share
Price / Book5.72

Profitability

Trailing EPS$5.76
Net Income$16.54 billion
Net Margins21.28%
Return on Equity27.38%
Return on Assets13.20%

Miscellaneous

Employees126,400
Outstanding Shares2,686,520,000

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Tuesday, January 2nd. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share on Tuesday, March 13th. This represents a $3.36 annualized dividend and a dividend yield of 2.33%. The ex-dividend date is Monday, February 26th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings results on Tuesday, January, 23rd. The company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.72 by $0.02. The business earned $20.20 billion during the quarter, compared to analysts' expectations of $20.08 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company's revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the business posted $1.58 EPS. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY18 earnings guidance on Tuesday, January, 23rd. The company provided EPS guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.87. The company issued revenue guidance of $80.6-81.4 billion, compared to the consensus revenue estimate of $80.71 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2018?

18 Wall Street analysts have issued 12 month target prices for Johnson & Johnson's stock. Their predictions range from $110.00 to $165.00. On average, they anticipate Johnson & Johnson's share price to reach $145.41 in the next year. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment decelerated in the first half of 2017 as a number of key growth drivers like Remicade and Concerta are facing competition.  However, sales growth accelerated in Q3 and the positive trend is expected to continue in Q4. We believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. J&J’s shares have outperformed the industry this year so far.  However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern." (12/12/2017)
  • 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 3. UBS Group AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer (Age 56)
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President (Age 59)
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President (Age 54)
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer (Age 55)
  • Michael H. Ullmann, Executive Vice President, General Counsel (Age 58)
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals (Age 54)
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer (Age 55)
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman (Age 58)
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director (Age 64)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.47%), Chevy Chase Trust Holdings Inc. (0.10%), First Manhattan Co. (0.09%), National Pension Service (0.08%), Marathon Asset Management LLP (0.07%) and Hexavest Inc. (0.07%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, First Manhattan Co., Exxonmobil Investment Management Inc. TX, Country Trust Bank, Wasatch Advisors Inc., Gateway Investment Advisers LLC, Strs Ohio and Sit Investment Associates Inc.. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including Cornerstone Investment Partners LLC, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, National Pension Service, McCollum Christoferson Group LLC, Hexavest Inc., Marathon Asset Management LLP and Sawyer & Company Inc. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $144.45.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $389.20 billion and generates $71.89 billion in revenue each year. The company earns $16.54 billion in net income (profit) each year or $5.76 on an earnings per share basis. Johnson & Johnson employs 126,400 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is 1 Johnson And Johnson Plz, NEW BRUNSWICK, NJ 08933-0001, United States. The company can be reached via phone at +1-732-5242455.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  516 (Vote Outperform)
Underperform Votes:  617 (Vote Underperform)
Total Votes:  1,133
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Johnson & Johnson (NYSE:JNJ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.222.332.322.32
Ratings Breakdown: 4 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $145.41$145.12$143.56$132.12
Price Target Upside: 0.52% upside2.82% upside0.81% upside3.26% downside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018Credit Suisse GroupSet Price TargetHold$154.00N/AView Rating Details
1/12/2018Wells Fargo & CoReiterated RatingOutperform -> Outperform$155.00 -> $160.00LowView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeOverweight -> NeutralLowView Rating Details
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00MediumView Rating Details
10/23/2017CitigroupBoost Price TargetBuy$140.00 -> $149.00N/AView Rating Details
10/16/2017Jefferies GroupBoost Price TargetBuy$157.00 -> $160.00N/AView Rating Details
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017CowenReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017Morgan StanleyReiterated RatingHold$140.00 -> $145.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/18/2017Stifel NicolausBoost Price TargetHold -> Hold$140.00 -> $142.00N/AView Rating Details
10/18/2017Leerink SwannReiterated RatingOutperform -> Outperform$150.00 -> $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/20/2017Goldman Sachs GroupDowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
7/21/2017BTIG ResearchDowngradeNeutral -> Sell$110.00LowView Rating Details
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
8/19/2016Deutsche BankReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James FinancialReiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
1/27/2016Independent ResearchSet Price TargetNeutral$108.00N/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/17/2018N/AView Earnings Details
1/23/2018Q4 2017$1.72$1.74$20.08 billion$20.20 billionViewN/AView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.29 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
10/19/2010Q3 2010$1.15$1.23ViewN/AView Earnings Details
7/20/2010Q2 2010$1.21$1.21ViewN/AView Earnings Details
4/20/2010Q1 2010$1.27$1.29ViewN/AView Earnings Details
1/26/2010Q4 2009$0.97$1.02ViewN/AView Earnings Details
10/13/2009Q3 2009$1.13$1.20ViewN/AView Earnings Details
7/14/2009Q2 2009$1.12$1.15ViewN/AView Earnings Details
4/14/2009Q1 2009$1.21$1.26ViewN/AView Earnings Details
1/20/2009Q4 2008$0.92$0.94ViewN/AView Earnings Details
10/14/2008Q3 2008$1.11$1.17ViewN/AView Earnings Details
7/15/2008Q2 2008$1.13$1.18ViewN/AView Earnings Details
4/15/2008Q1 2008$1.20$1.26ViewN/AView Earnings Details
1/22/2008Q4 2007$0.86$0.88ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2018 EPS Consensus Estimate: $7.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.99$1.99$1.99
Q2 20181$2.01$2.01$2.01
Q3 20181$2.18$2.18$2.18
Q4 20181$1.81$1.81$1.81
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Johnson & Johnson (NYSE:JNJ) Dividend Information

Next Dividend:3/13/2018
Annual Dividend:$3.36
Dividend Yield:2.27%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio:58.33% (Trailing 12 Months of Earnings)
46.15% (Based on This Year's Estimates)
42.75% (Based on Next Year's Estimates)
Track Record:55 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/2/2018quarterly$0.842.39%2/26/20182/27/20183/13/2018
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.72%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88230,342View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52226,693View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00127,650View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.2526,520View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46157,819View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.3528,660View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.0543,630View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.0028,725View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.8929,682View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00122,543View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.2037,735View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.5220,803View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.0090,294View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.6015,647View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.0088,159View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.2055,427View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Johnson & Johnson (NYSE JNJ) News Headlines

Source:
DateHeadline
Johnson & Johnson loses $10.7B after sweeping US tax changesJohnson & Johnson loses $10.7B after sweeping US tax changes
marketbeat.com - January 23 at 8:55 AM
Johnson & Johnson (JNJ) Issues FY18 Earnings GuidanceJohnson & Johnson (JNJ) Issues FY18 Earnings Guidance
www.americanbankingnews.com - January 23 at 8:50 AM
Johnson & Johnson (JNJ) Posts  Earnings ResultsJohnson & Johnson (JNJ) Posts Earnings Results
www.americanbankingnews.com - January 23 at 8:50 AM
Dow Analyst Moves: JNJDow Analyst Moves: JNJ
www.msn.com - January 22 at 3:45 PM
Johnson & Johnson earnings: Expect a strong quarter for drug salesJohnson & Johnson earnings: Expect a strong quarter for drug sales
www.marketwatch.com - January 22 at 3:45 PM
[$$] Johnson & Johnsons Earnings Are Coming. Heres What to Watch.[$$] Johnson & Johnson's Earnings Are Coming. Here's What to Watch.
finance.yahoo.com - January 22 at 3:45 PM
These 2 Developments Could Accelerate Johnson & Johnsons Next Acquisition - Motley FoolThese 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition - Motley Fool
www.fool.com - January 22 at 8:14 AM
Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 blnSanofi to buy U.S. haemophilia group Bioverativ for $11.6 bln
finance.yahoo.com - January 22 at 8:14 AM
Johnson & Johnson’s Consumer Segment: 4Q17 EstimatesJohnson & Johnson’s Consumer Segment: 4Q17 Estimates
finance.yahoo.com - January 22 at 8:14 AM
What Analysts Recommend for Bristol-Myers Squibb in January 2018What Analysts Recommend for Bristol-Myers Squibb in January 2018
finance.yahoo.com - January 22 at 8:14 AM
These 2 Developments Could Accelerate Johnson & Johnson's Next AcquisitionThese 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition
finance.yahoo.com - January 22 at 8:14 AM
Johnson & Johnson Is Trading at an All-Time High—What’s Next?Johnson & Johnson Is Trading at an All-Time High—What’s Next?
finance.yahoo.com - January 22 at 8:14 AM
Johnson & Johnson (JNJ) Receives Average Recommendation of "Hold" from AnalystsJohnson & Johnson (JNJ) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 20 at 8:08 AM
Upcoming Consumer Earnings Reports to Watch: JNJ, F, SBUXUpcoming Consumer Earnings Reports to Watch: JNJ, F, SBUX
www.zacks.com - January 19 at 3:18 PM
Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?
finance.yahoo.com - January 19 at 3:18 PM
JNJ’s Recent Spine Business Developments: 4Q17 ExpectationsJNJ’s Recent Spine Business Developments: 4Q17 Expectations
finance.yahoo.com - January 19 at 3:18 PM
Should You Be Tempted To Sell Johnson & Johnson (NYSE:JNJ) Because Of Its PE Ratio?Should You Be Tempted To Sell Johnson & Johnson (NYSE:JNJ) Because Of Its PE Ratio?
finance.yahoo.com - January 19 at 3:18 PM
Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label ExpansionPharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion
finance.yahoo.com - January 19 at 7:10 AM
FY2019 EPS Estimates for Johnson & Johnson (JNJ) Raised by AnalystFY2019 EPS Estimates for Johnson & Johnson (JNJ) Raised by Analyst
www.americanbankingnews.com - January 18 at 9:38 PM
J&J (JNJ) Hits New 52-Week High: Whats Driving the Stock?J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
www.zacks.com - January 18 at 3:18 PM
J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?
finance.yahoo.com - January 18 at 3:18 PM
Johnson & Johnson Issues Statement on ZYTIGA® Inter Partes ReviewsJohnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews
finance.yahoo.com - January 18 at 3:18 PM
Merck’s & Co.’s Valuation in January 2018Merck’s & Co.’s Valuation in January 2018
finance.yahoo.com - January 18 at 3:18 PM
Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis LabelAmgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label
finance.yahoo.com - January 18 at 3:18 PM
Johnson & Johnson (JNJ) Says It Strongly Disagrees with USPTO ... - StreetInsider.comJohnson & Johnson (JNJ) Says It Strongly Disagrees with USPTO ... - StreetInsider.com
www.streetinsider.com - January 18 at 6:13 AM
Brokers Set Expectations for Johnson & Johnsons FY2018 Earnings (JNJ)Brokers Set Expectations for Johnson & Johnson's FY2018 Earnings (JNJ)
www.americanbankingnews.com - January 17 at 5:58 PM
Stats on Johnson & Johnson - Motley FoolStats on Johnson & Johnson - Motley Fool
www.fool.com - January 17 at 3:18 PM
J&J diabetes business attracts Chinese interest - Seeking AlphaJ&J diabetes business attracts Chinese interest - Seeking Alpha
seekingalpha.com - January 17 at 3:18 PM
Ortho-Clinical Diagnostics SA -- Moodys affirms Ortho-Clinicals ratings, outlook revised to stableOrtho-Clinical Diagnostics SA -- Moody's affirms Ortho-Clinical's ratings, outlook revised to stable
finance.yahoo.com - January 17 at 3:18 PM
Johnson & Johnson trying to sell its diabetes care business to Chinese buyers for up to $4 billionJohnson & Johnson trying to sell its diabetes care business to Chinese buyers for up to $4 billion
www.cnbc.com - January 17 at 1:47 PM
Is Johnson & Johnson a Buy? - Motley FoolIs Johnson & Johnson a Buy? - Motley Fool
www.fool.com - January 16 at 6:04 AM
Johnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on TuesdayJohnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 16 at 2:50 AM
Is Johnson & Johnson a Buy?Is Johnson & Johnson a Buy?
www.fool.com - January 15 at 11:28 PM
Vetr Upgrades Johnson & Johnson (JNJ) to BuyVetr Upgrades Johnson & Johnson (JNJ) to Buy
www.americanbankingnews.com - January 14 at 8:50 PM
Trump looks to revamp major Medicaid requirementsTrump looks to revamp major Medicaid requirements
finance.yahoo.com - January 13 at 3:17 PM
Johnson & Johnson (JNJ) Stock Rating Reaffirmed by Wells Fargo & CoJohnson & Johnson (JNJ) Stock Rating Reaffirmed by Wells Fargo & Co
www.americanbankingnews.com - January 12 at 11:16 PM
Johnson & Johnson (JNJ) PT Raised to $160 at Wells Fargo on Q4 Earnings Preview; Potential Upside to 2018 ... - StreetInsider.comJohnson & Johnson (JNJ) PT Raised to $160 at Wells Fargo on Q4 Earnings Preview; 'Potential Upside to 2018 ... - StreetInsider.com
www.streetinsider.com - January 12 at 3:17 PM
Johnson & Johnson (JNJ) Reports First Patient Enrolled in ... - StreetInsider.comJohnson & Johnson (JNJ) Reports First Patient Enrolled in ... - StreetInsider.com
www.streetinsider.com - January 12 at 5:52 AM
Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare FirmsChanges to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms
finance.yahoo.com - January 12 at 5:52 AM
Johnson & Johnson (JNJ) Reports First Patient Enrolled in WaveCrest Investigational Device Exemption TrialJohnson & Johnson (JNJ) Reports First Patient Enrolled in WaveCrest Investigational Device Exemption Trial
www.streetinsider.com - January 11 at 3:18 PM
Pharmas Tax-Cut Plans Look Pretty DullPharma's Tax-Cut Plans Look Pretty Dull
finance.yahoo.com - January 11 at 3:18 PM
Johnson & Johnson chief Gorsky thumbs up new tax law, plans ... - Seeking AlphaJohnson & Johnson chief Gorsky thumbs up new tax law, plans ... - Seeking Alpha
seekingalpha.com - January 11 at 5:58 AM
JNJ CEO: DACA important at a personal levelJNJ CEO: DACA important at a personal level
finance.yahoo.com - January 11 at 5:58 AM
JNJ employee expresses gratitude to CEO Alex Gorsky for D...JNJ employee expresses gratitude to CEO Alex Gorsky for D...
finance.yahoo.com - January 11 at 5:58 AM
Putting On The Brakes: Rally Takes Breather As Bond Yields Hit 10-Month HighPutting On The Brakes: Rally Takes Breather As Bond Yields Hit 10-Month High
finance.yahoo.com - January 10 at 3:18 PM
Why JNJs Stock Has Healthy Gains AheadWhy JNJ's Stock Has Healthy Gains Ahead
finance.yahoo.com - January 10 at 3:18 PM
Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit - ReutersBayer, J&J win reversal of $28 million verdict in Xarelto lawsuit - Reuters
www.reuters.com - January 10 at 6:07 AM
Johnson & Johnson Wants to Create a Crisis -- and Thats Great for Investors - Motley FoolJohnson & Johnson Wants to Create a Crisis -- and That's Great for Investors - Motley Fool
www.fool.com - January 10 at 6:07 AM
Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuitBayer, J&J win reversal of $28 million verdict in Xarelto lawsuit
finance.yahoo.com - January 10 at 6:07 AM
3 Dividend Stocks That Cut Bigger Checks Than Johnson & Johnson3 Dividend Stocks That Cut Bigger Checks Than Johnson & Johnson
www.fool.com - January 9 at 9:02 PM

SEC Filings

Johnson & Johnson (NYSE:JNJ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Johnson & Johnson (NYSE JNJ) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.